263 related articles for article (PubMed ID: 21502627)
1. Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin.
Slater JL; Howard SJ; Sharp A; Goodwin J; Gregson LM; Alastruey-Izquierdo A; Arendrup MC; Warn PA; Perlin DS; Hope WW
Antimicrob Agents Chemother; 2011 Jul; 55(7):3075-83. PubMed ID: 21502627
[TBL] [Abstract][Full Text] [Related]
2. Breakthrough invasive candidiasis in patients on micafungin.
Pfeiffer CD; Garcia-Effron G; Zaas AK; Perfect JR; Perlin DS; Alexander BD
J Clin Microbiol; 2010 Jul; 48(7):2373-80. PubMed ID: 20421445
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.
Howard SJ; Livermore J; Sharp A; Goodwin J; Gregson L; Alastruey-Izquierdo A; Perlin DS; Warn PA; Hope WW
Antimicrob Agents Chemother; 2011 Oct; 55(10):4880-7. PubMed ID: 21807969
[TBL] [Abstract][Full Text] [Related]
4. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.
Andes DR; Diekema DJ; Pfaller MA; Marchillo K; Bohrmueller J
Antimicrob Agents Chemother; 2008 Oct; 52(10):3497-503. PubMed ID: 18625768
[TBL] [Abstract][Full Text] [Related]
5. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains.
Castanheira M; Woosley LN; Diekema DJ; Messer SA; Jones RN; Pfaller MA
Antimicrob Agents Chemother; 2010 Jun; 54(6):2655-9. PubMed ID: 20368396
[TBL] [Abstract][Full Text] [Related]
6. Effects of Echinocandins in Combination with Nikkomycin Z against Invasive Candida albicans Bloodstream Isolates and the
Cheung YY; Hui M
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28827418
[TBL] [Abstract][Full Text] [Related]
7. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
Arendrup MC; Perlin DS; Jensen RH; Howard SJ; Goodwin J; Hope W
Antimicrob Agents Chemother; 2012 May; 56(5):2435-42. PubMed ID: 22354305
[TBL] [Abstract][Full Text] [Related]
8. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.
Park S; Kelly R; Kahn JN; Robles J; Hsu MJ; Register E; Li W; Vyas V; Fan H; Abruzzo G; Flattery A; Gill C; Chrebet G; Parent SA; Kurtz M; Teppler H; Douglas CM; Perlin DS
Antimicrob Agents Chemother; 2005 Aug; 49(8):3264-73. PubMed ID: 16048935
[TBL] [Abstract][Full Text] [Related]
9. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1.
Balashov SV; Park S; Perlin DS
Antimicrob Agents Chemother; 2006 Jun; 50(6):2058-63. PubMed ID: 16723566
[TBL] [Abstract][Full Text] [Related]
10. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.
Pfaller MA; Diekema DJ; Andes D; Arendrup MC; Brown SD; Lockhart SR; Motyl M; Perlin DS;
Drug Resist Updat; 2011 Jun; 14(3):164-76. PubMed ID: 21353623
[TBL] [Abstract][Full Text] [Related]
11. Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.
Lepak A; Castanheira M; Diekema D; Pfaller M; Andes D
Antimicrob Agents Chemother; 2012 Nov; 56(11):5875-82. PubMed ID: 22948870
[TBL] [Abstract][Full Text] [Related]
12. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.
Andes D; Diekema DJ; Pfaller MA; Bohrmuller J; Marchillo K; Lepak A
Antimicrob Agents Chemother; 2010 Jun; 54(6):2497-506. PubMed ID: 20385855
[TBL] [Abstract][Full Text] [Related]
13. Echinocandin antifungal drugs in fungal infections: a comparison.
Chen SC; Slavin MA; Sorrell TC
Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
[TBL] [Abstract][Full Text] [Related]
14. Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity.
Niimi K; Monk BC; Hirai A; Hatakenaka K; Umeyama T; Lamping E; Maki K; Tanabe K; Kamimura T; Ikeda F; Uehara Y; Kano R; Hasegawa A; Cannon RD; Niimi M
J Antimicrob Chemother; 2010 May; 65(5):842-52. PubMed ID: 20233776
[TBL] [Abstract][Full Text] [Related]
15. Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans.
Wiederhold NP; Grabinski JL; Garcia-Effron G; Perlin DS; Lee SA
Antimicrob Agents Chemother; 2008 Nov; 52(11):4145-8. PubMed ID: 18794385
[TBL] [Abstract][Full Text] [Related]
16. Paradoxical antifungal activity and structural observations in biofilms formed by echinocandin-resistant Candida albicans clinical isolates.
Walraven CJ; Bernardo SM; Wiederhold NP; Lee SA
Med Mycol; 2014 Feb; 52(2):131-139. PubMed ID: 24576999
[TBL] [Abstract][Full Text] [Related]
17. Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance.
Ben-Ami R; Garcia-Effron G; Lewis RE; Gamarra S; Leventakos K; Perlin DS; Kontoyiannis DP
J Infect Dis; 2011 Aug; 204(4):626-35. PubMed ID: 21791665
[TBL] [Abstract][Full Text] [Related]
18. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.
Garcia-Effron G; Park S; Perlin DS
Antimicrob Agents Chemother; 2009 Jan; 53(1):112-22. PubMed ID: 18955538
[TBL] [Abstract][Full Text] [Related]
19. Positions and numbers of FKS mutations in Candida albicans selectively influence in vitro and in vivo susceptibilities to echinocandin treatment.
Lackner M; Tscherner M; Schaller M; Kuchler K; Mair C; Sartori B; Istel F; Arendrup MC; Lass-Flörl C
Antimicrob Agents Chemother; 2014 Jul; 58(7):3626-35. PubMed ID: 24733467
[TBL] [Abstract][Full Text] [Related]
20. Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.
Petraitiene R; Petraitis V; Hope WW; Walsh TJ
Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S643-51. PubMed ID: 26567283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
